DHAKA, Sept 18, 2025: Bangladesh is set to make a mark in the global pharmaceuticals market with the launch of a state-of-the-art penicillin antibiotics facility by Healthcare Life Science Ltd (HLSL) in the National Special Economic Zone (NSEZ), Chattogram. The plant, the first of its kind in the country, is spread over 40 acres and backed by a $50 million investment.
The facility will produce over 15 penicillin-based formulations in tablets, capsules, injectables, and prefilled syringes, fully complying with US FDA, WHO-GMP, and EU-GMP standards, enabling exports to regulated and emerging markets. HLSL expects annual export earnings of Tk50 crore in the first three years, rising to Tk100-200 crore by the fourth and fifth years.
Equipped with cutting-edge R&D and quality control infrastructure, the plant will manufacture 60 million tablets, 90 million capsules, and 4 million units of injectables and liquid ampoules annually, serving both domestic and international markets. The remaining 30 acres are earmarked for future expansion into biotech and specialty medicines, creating jobs for over 7,200 people.
Muhammad Zahid Al Beruni, head of operations at HLSL, said the facility signals that Bangladesh is ready to move up the global pharmaceutical value chain. The project is part of a broader industrialisation strategy by the Bangladesh Economic Zones Authority (BEZA) and positions NSEZ as a growing hub for large-scale, environmentally safe industrial investment.
